<DOC>
	<DOCNO>NCT00562497</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled study investigate efficacy safety Prochymal™ versus placebo combination corticosteroid initial therapy acute GVHD . Corticosteroids primary therapy patient previously untreated acute GVHD historical publish data define expect 35 % complete response ( CR ) Day +28 use therapy .</brief_summary>
	<brief_title>Efficacy Safety Prochymal™ Infusion Combination With Corticosteroids Treatment Newly Diagnosed Acute GVHD</brief_title>
	<detailed_description>Subjects treat total 6 infusion investigational agent first 4 week study . Four infusion administer first two week ( twice weekly ) , two infusion administer next two week ( weekly ) . Subjects assign active treatment group receive Prochymal™ . Subjects assign non active treatment group receive placebo ( excipient , less cell ) . It recommend subject receive six infusion . The discontinuation investigational agent allow GVHD worsen subsequent need salvage therapy . All infusion must give least 3 day apart . Subjects evaluate efficacy safety death , withdrawal 90 study day randomization , whichever occur first . Study unblinded data analyze Day 90 post 1st infusion ( Day 0 ) follow final subject enrollment . Subjects follow safety 12 month post 1st infusion ( Day 0 ) .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Subjects must 18 year 70 year age , inclusive Subjects must receive allogeneic hematopoietic stem cell transplant use either bone marrow , peripheral blood stem cell cord blood administer donor leukocyte infusion . Subjects must newly diagnose Grades BD acute GVHD . Biopsy confirmation GVHD strongly recommend require . Randomization delay await biopsy pathology result . Subjects must randomize treat corticosteroid ( 12 mg/kg/d methylprednisolone , equivalent ) Prochymal™/placebo within 72 hour onset acute GVHD . Subjects must adequate renal function define : Calculated Creatinine Clearance &gt; 30mL/min use CockroftGault equation Subjects woman childbearing potential , must nonpregnant , breastfeed , use adequate contraception . Male subject must use adequate contraception Subject must minimum Karnofsky Performance Level least 30 time study entry Subject ( legal representative appropriate ) must capable provide write informed consent . Subject previously treat systemic immunosuppressive therapy acute GVHD Subject underlie current medical psychiatric condition , opinion Investigator , would interfere evaluation subject include uncontrolled infection , heart failure , pulmonary hypertension , etc . Subjects may receive investigational agent ( approved FDA indication ) concurrently study participation within 30 day randomization . Subject know allergy bovine porcine product DMSO Subject receive transplant solid tumor disease . Subject require 2L/min oxygen maintain stable SaO2 great equal 92 % Subject require renal dopamine dose great 13 mcg/kg/min maintain renal blood flow associate renal failure improve urinary output .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute GVHD</keyword>
	<keyword>Acute Graft Versus Host Disease</keyword>
</DOC>